Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | NPY4R | P50391 | 4/20 | 0.31 |
| ▸ | NPY1R | P25929 | 3/20 | 0.31 |
| ▸ | NPY2R | P49146 | 3/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20130627 | 0.89 | ALOX15 (0.34) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL21541002 | 0.88 | ALOX15 (0.34) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL23222830 | 0.87 | ALOX15 (0.36) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL20130639 | 0.87 | ALOX15 (0.36) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL20100647 | 0.85 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL26390131 | 0.84 | ALOX15 (0.32) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL20130658 | 0.84 | ALOX15 (0.35) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL24917432 | 0.84 | ALOX15 (0.36) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL23771470 | 0.83 | ALOX15 (0.34) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL20104623 | 0.83 | ALOX15 (0.34) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | US | disclosed |
| US-11780900-B2 | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | Janssen Sciences Ireland Unlimited Company (IE) | 2023-10-10 | — | — | US | disclosed |
| US-11780900-B2 | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | Janssen Sciences Ireland Unlimited Company (IE) | 2023-10-10 | — | — | US | disclosed |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-26 | — | — | US | disclosed |
| US-11732019-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-22 | — | — | US | disclosed |
| US-11591379-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-28 | — | — | US | disclosed |
| US-20230057847-A1 | GLP2 RECEPTOR AGONISTS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2023-02-23 | — | — | US | disclosed |
| US-20210253661-A1 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2021-08-19 | — | — | US | disclosed |
| US-20210206822-A1 | Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-08 | — | — | US | disclosed |
| WO-2021113524-A2 | GLP2 RECEPTOR AGONISTS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-10 | — | — | WO | disclosed |
| US-10968264-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-06 | — | — | US | disclosed |
| US-10961293-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICS NV (BE) | 2021-03-30 | — | — | US | disclosed |
| US-10875902-B2 | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-29 | — | — | US | disclosed |
| US-20200283491-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-10 | — | — | US | disclosed |
| US-10640544-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-05 | — | — | US | disclosed |
| US-20190345214-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-14 | — | — | US | disclosed |
| US-20190298849-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-03 | — | — | US | disclosed |
| US-20180127476-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-10 | — | — | US | disclosed |
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961293-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | ALOX15 1793/4885MEN1 1346/4885CYP1A2 4129/4885 |
| US-20210206822-A1 | Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors | NPY4R, NPY5R, NPY1R | ALOX15 1793/4885MEN1 1346/4885CYP1A2 4129/4885 |
| US-20210253661-A1 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | GLP1R, GIPR, IAPP | ALOX15 4087/4885MEN1 1397/4885CYP1A2 4757/4885 |
| US-20200283491-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | ALOX15 2953/4885MEN1 1303/4885CYP1A2 4749/4885 |
| US-10875902-B2 | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | GLP1R, GIPR, IAPP | ALOX15 4087/4885MEN1 1397/4885CYP1A2 4757/4885 |
| US-20190298849-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | ALOX15 2953/4885MEN1 1303/4885CYP1A2 4749/4885 |
| US-20230057847-A1 | GLP2 RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GRPR | ALOX15 3747/4885MEN1 736/4885CYP1A2 4017/4885 |
| US-11732019-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | ALOX15 1793/4885MEN1 1346/4885CYP1A2 4129/4885 |
| US-20180127476-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | ALOX15 1793/4885MEN1 1346/4885CYP1A2 4129/4885 |
| US-10640544-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | ALOX15 2953/4885MEN1 1303/4885CYP1A2 4749/4885 |
| US-11780900-B2 | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | GLP1R, GIPR, IAPP | ALOX15 4087/4885MEN1 1397/4885CYP1A2 4757/4885 |
| US-11591379-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | ALOX15 2953/4885MEN1 1303/4885CYP1A2 4749/4885 |
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | ALOX15 2953/4885MEN1 1303/4885CYP1A2 4749/4885 |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | ALOX15 2953/4885MEN1 1303/4885CYP1A2 4749/4885 |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | ALOX15 2953/4885MEN1 1303/4885CYP1A2 4749/4885 |
| US-10968264-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | ALOX15 1793/4885MEN1 1346/4885CYP1A2 4129/4885 |
| US-20190345214-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | ALOX15 1793/4885MEN1 1346/4885CYP1A2 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.